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Abstract: The tumor necrosis factor-α-induced protein 8-like (TIPE/TNFAIP8) family is a recently
identified family of proteins that is strongly associated with the regulation of immunity and
tumorigenesis. This family is comprised of four members, namely, tumor necrosis factor-α-induced
protein 8 (TIPE/TNFAIP8), tumor necrosis factor-α-induced protein 8-like 1 (TIPE1/TNFAIP8L1),
tumor necrosis factor-α-induced protein 8-like 2 (TIPE2/TNFAIP8L2), and tumor necrosis
factor-α-induced protein 8-like 3 (TIPE3/TNFAIP8L3). Although the proteins of this family were
initially described as regulators of tumorigenesis, inflammation, and cell death, they are also found
to be involved in the regulation of autophagy and the transfer of lipid secondary messengers, besides
contributing to immune function and homeostasis. Interestingly, despite the existence of a significant
sequence homology among the four members of this family, they are involved in different biological
activities and also exhibit remarkable variability of expression. Furthermore, this family of proteins is
highly deregulated in different human cancers and various chronic diseases. This review summarizes
the vivid role of the TIPE family of proteins and its association with various signaling cascades in
diverse chronic diseases.
Int. J. Mol. Sci. 2018, 19, 2974; doi:10.3390/ijms19102974 www.mdpi.com/journal/ijms
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1. Introduction
The tumor necrosis factor-α-induced protein 8 (TIPE/TNFAIP8/Oxi-α) family is a newly
identified family of proteins that is involved in the regulation of immunity and tumorigenesis.
This family is comprised of four members, namely, TIPE or TNFAIP8 (tumor necrosis factor-α-induced
protein 8), TIPE1 (TNFAIP8-like 1, or TNFAIP8L1), TIPE2 (TNFAIP8-like 2 or TNFAIP8L2), and TIPE3
(TNFAIP8-like 3 or TNFAIP8L3) [1]. Despite the fact that all the four proteins of this family share
a significant sequence homology (~54% sequence identity), they are involved in the regulation of
different cellular activities [2–5].
TIPE, the most extensively studied member of this family, is a transcription factor nuclear factor-
κ-B inducible, anti-apoptotic, and oncogenic molecule that is associated with prognosis of different
malignancies. It is a 21-kDa cytoplasmic protein that was initially identified in human head and neck
squamous cell carcinoma [5–10]. It is expressed in different human normal tissues with relatively
higher levels in placenta and lymphoid tissues. The open reading frame of this protein bears a sequence
in the amino terminus that displays a notable homology to the death effector domain II of the cell death
regulatory protein, Fas-associated death domain-like interleukin-1β-converting enzyme-inhibitory
protein (FLIP) [11]. TIPE is associated with the immune regulation of CD4+ T lymphocytes and inhibits
autophagy under oxidative stress through the mammalian target of rapamycin (mTOR)-dependent
pathway [3,12,13]. Notably, different transcript variants of this TIPE gene were recently listed in the
NCBI databank. However, currently no study has described their distinguished roles or depicted
the factors that regulate their expression. A study by Lowe and group reported TIPE variant 2 as
an oncogenic gene product that may regulate different processes in tumor cells such as proliferative
signaling, resistance to cell death, and evasion of growth suppressors. On the other hand, other
variants are normally downregulated in cancer (variant 1) or show minimal expression in cancer or
normal tissues (variant 3–variant 6) [14].
TIPE1 (tumor necrosis factor-α-induced protein 8-like 1) is a recently identified member of the
TIPE family that can act as a cell death regulator. It is regarded as a pro-apoptotic factor with the
ability to cause increased apoptotic functions. Currently, there is little information available about the
role of TIPE1. The information on its biological activity under both physiological and pathological
conditions remains ambiguous [4,5,15–17]. It was reported to be distributed in different mouse tissues
except for mature B and T lymphocytes. Further, TIPE1 was speculated to be associated with cardiac
decompensation linked with diabetes and to interact with FBXW5 and caspase-8. Besides, different
post-translational modifications were also predicted to exist in the case of TIPE1 [2,16].
TIPE2 (tumor necrosis factor-α-induced protein 8-like 2), the third member of this family,
is a latterly discovered negative regulator of innate, as well as cellular immunity, with sizable sequence
homology with the other members of the family [18–20]. It is a cytoplasmic protein consisting of 184
amino acids and is expressed preferentially in lymphoid tissues and some non-lymphoid tissues [19,21].
This protein was initially identified as an abnormally expressed gene in the inflamed spinal cord of
experimental autoimmune encephalomyelitic mice [22,23]. Further, TIPE2 was found to be expressed
in varied cell types such as neurons in the brain and brainstem; hepatocytes; squamous epithelial
cells in the cervix and esophagus; glandular epithelial cells in the colon, stomach, and appendix; and
transitional epithelial cells in the ureter and bladder [24]. It negatively regulates the functions of
toll-like receptor (TLR) and T cell receptor, and its selective expression in the immune system averts
hyper responsiveness and maintains immune homeostasis [22,23,25]. Further, it is an inhibitor of the
nuclear factor κ-light-chain-enhancer of activated B cells (NF-κB) and mitogen-activated protein kinase
(MAPK) signaling pathways and contributes to the reduced activation of activator protein-1 (AP-1)
and NF-κB [5,26,27]. It also acts as an inhibitor of Rac, which is a GTPase involved in the promotion of
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trailing-edge polarization [28]. A recent genome-wide expression profiling analysis reveals TIPE2 to
function as an immune checkpoint regulator of inflammation and metabolism. This finding depicts
that during the course of inflammation, the expression of TIPE2 may be downregulated plausibly due
to its altered epigenetic status, which in turn results in the upregulation of the expression of lipid
biosynthesis genes, mitochondrial respiration, and inflammation [29].
TIPE3 (tumor necrosis factor-α-induced protein 8-like 3), the newest member of TIPE family,
is located on human chromosome 15. It functions as a transfer protein for lipid second messengers
PIP2 (phosphatidylinositol 4,5-bisphosphate) and PIP3 (phosphatidylinositol 3,4,5-trisphosphate),
and enhances their level in the plasma membrane [1,30,31]. This protein is expressed in various human
organs and is highly upregulated in several human cancers such as cervical cancer, colon cancer,
esophageal cancer, and lung cancer [5,32].
Furthermore, the crystal structures of two members of the TIPE family, namely, TIPE2 and TIPE3
from Homo sapiens, have been determined. Both of them possess a central hydrophobic cavity that
is proposed as a binding site for cofactors, occupied by two long electrostatic densities, which are
plausibly phospholipid in nature [3,19,33,34]. Moreover, these phospholipids were observed to share
similar binding modes that involve the exposure of the inositol head group outside and insertion of the
lipid tails into the cavity. In addition, all the lipid molecules interact with the critical, positively charged
residues as per molecular interaction studies, i.e., Arg 75 and −91 in TIPE2, and Arg 181 and 197 in
TIPE3, indicating the similar binding fashion of the phosphoinositides to the TH domain of this protein
family [35]. Interestingly, the high-resolution crystal structure of TIPE2 clearly reveals that it possesses
a unique yet previously uncharacterized fold that gives TIPE2 a unique structure and topology that is
different from that of death effector domain (DED). The structure of TIPE2, which comprises around
150 amino acids, is reasonably larger than that of the DED, as it usually contains a total of 90 amino
acids. Again, the topology of TIPE2 is different from that of a DED, as it was observed that N-to-C
arrangement of TIPE2 is identical to the C-to-N topology diagram of DED. Therefore, the topology of
TIPE2 seems to be a mirror image of that of the DED [34]. Additionally, the crystal structure of TIPE
from Mus musculus (mTIPE) was also determined. The overall shape of mTIPE bears a resemblance to
a water dipper. Its cylindrical domain contains two long electron densities and has a dimension of
48 × 31 × 30 Å linked to an N-terminal grip-like domain of length ~35 Å that comprises of 20 residues.
It possesses a hydrophobic cavity of depth around 20 Å, a diameter of around 7 Å, and a volume of
837 Å, which is lined with highly conserved hydrophobic residues, thereby facilitating the binding of
hydrophobic cofactors or substrates inside the cavity [3].
Aforementioned, different in vitro and in vivo studies have revealed that this family of proteins
plays a crucial role in inflammatory responses and tumorigenesis (Table 1; [5]). Interestingly,
the expression analyses in clinical settings have also demonstrated these proteins to be highly
deregulated in different cancers and various chronic diseases (Figure 1).
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Table 1. Different chronic diseases and signaling pathways with known associations with the TIPE family of proteins.
Disease Model Protein Involved Targets Associated/Outcome References
Cancers
Bladder cancer T24 cells ↑TIPE3 ↑PI3K-Akt, ↑MEK-ERK [31]
Breast cancer
Tissue samples ↑TIPE tumor progression [8]
MDA-MB-231 and MCF-7 cells ↑TIPE2 ↓β-catenin, ↓cyclin D1, ↓c-Myc [36]
MDA-MB-231 cells transfected into the dorsal flank of female BALB/c nude mice (4–5
weeks old); two groups (vector group and TIPE2 group) ↓tumor growth
MCF-7 cells ↓TIPE ↑p21 [14]
MDA-MB-231 and LM2-4175 cells ↓TIPE
↑SNX1, ↑NR4A1, ↑AP2A1, ↓IL5
↓SRC, ↓MAPT, ↓NEK2, ↓TRAF4,
↓PDCL, ↓GTF2F2, ↓GRAP2, ↓ABL1,
↓AKAP2, ↓GAP43, ↓PIK3CA, ↓EGFR,
[9]
HS578T and MCF-7 cells TIPE - [37]
MDA-MB-435 cells
MDA-MB 435 cells transfected via tail vein into female BALB/c mice (6–8 weeks old);
eight animals in vector group and 12 animals in TIPE group
↓TIPE ↓VEGFR-2, ↓MMP-1, ↓MMP-9 [38]
MCF-7 and MDA-MB-231 TIPE3 ↑MMP2, ↑uPA, ↑AKT, ↑NF-κB [32]
MDA-MB-231 cells ↑TIPE - [39]
Cervical cancer Tissue samples ↑TIPE platinum resistance [40]
Colon cancer
CACO2 and HCT116 cells ↑TIPE ↑cyclin D1, ↑phospho-Rb [41]
HT-29 cells ↓TIPE3 ↓PI3K-Akt [31]
HCT116 cells ↓TIPE ↑p21 [14]
HCT116 cells TIPE - [42]
Endometrial cancer Tumor specimens ↑TIPE ↑Ki-67, ↑MMP-9 [43]
ESCC
TE-1, TE-8, and TE-15 cells ↑TIPE - [44]
Eca109 cells ↓TIPE ↑apoptosis [6]
Gastric cancer
AGS and HGC-27 cells ↑TIPE2 ↓Akt, ↓ERK1/2 [45]
AGS cells xenografted female BALB/c nude mice (4-week-old); Five mice in
each group
AGS, HGC-27, and SGC-7901 cells ↑TIPE2 ↓Akt, ↑GSK3β [46]
BGC823 cells ↓TIPE caspase-3, -8, -9 [47]
BGC823 cells injected athymic nude mice; four groups containing six animals in
each group ↓TIPE ↓tumor growth
Tissue samples ↑TIPE ↑metastasis, ↓prognosis [48]
AGS, BGC-823, and SGC-7901 cells TIPE1 ↓Wnt/β-catenin, ↓MMP-2, ↓MMP-9 [49]
BGC-823 cells injected through tail vein into male nude mice (5–6 weeks old),
four groups (including control group)
Int. J. Mol. Sci. 2018, 19, 2974 5 of 19
Table 1. Cont.
Disease Model Protein Involved Targets Associated/Outcome References
MKN-28, SGC-7901, and MGC-803 cells ↑TIPE - [50]
Tissue samples ↑TIPE - [51]
AGS and HGC-27 cells ↑TIPE2 reversal of EMT [52]
Glioma U87, U251, and U373 MG cells ↑TIPE2 ↓Wnt/β-catenin, ↓EMT [53]
HCC
Bel7402, SK-Hep-1, HepG2, ↑TIPE ↓YAP phosphorylation [7]
SMMC7721 and Huh7 cells
Bel7402, SMMC7721, QSG770, HepG2, and HepG2.2.1 cells TIPE1 ↓Rac1 [16]
Subcutaneously transplanted H22 cells into male BALB/c mice (6–8 weeks old); two
groups (including control group) containing at least five mice in each cohort ↓tumor growth and weight
HepG2 cells TIPE2 ↓Erk1/2-NF-κB [27]
Lung cancer
H292 and A549 cells ↑TIPE1 ↓cyclin D1, cyclin B1, ↓caspase3, [15]
↓caspase 8, ↓MMP-2, ↓MMP-9
A549 cells engrafted into the flank of female BALB/c nude mice; two groups (control
group and TIPE1 group) containing five mice in each group ↑TIPE1 ↓tumor growth
H460 and H1299 cells ↑TIPE ↓phosphorylated LATS1 [54]
A549 cells ↓TIPE ↑p21 [14]
H1299 cells TIPE - [42]
Tissue samples ↑TIPE - [55]
H1975 and A549 cells ↑TIPE2 ↓Rac1, ↓VEGF [56]
Tissue samples ↑TIPE - [57]
H1975 and A549 cells ↑TIPE3 ↑Akt, ↑ERK [30]
A549 cells transfected into flanks of male BALB/c nude mice (4–6 weeks old), two
groups (mock and C-3 flag TIPE3) containing five mice in each group ↑tumor growth
NCI-H727 cells ↑TIPE3 - [31]
Tissue samples -
NCI-H460 and A549 cells
A549 cells injected into flanks of female BALB/c nude mice (4–6 weeks old); two
groups (Control and TIPE group) containing 10 mice in each group
↓TIPE ↓MDM2, ↓RAD51↓tumor volume [58]
Melanoma MDA-MB-435 cells ↓TIPE
↑NR4A1, ↑AP2A1, ↓TOP2A, ↓EGFR
↓PDCL, ↓GTF2F2, ↓IL5, ↓GRAP2,
↓AKAP2, ↓GAP43, ↓ABL1
[9]
NHL
Tissue samples ↑TIPE2 ↑prognosis [59]
514 NHL patients and 557 cancer-free controls TIPE TIPE polymorphism rs1045241C > T [60]
Osteosarcoma
143b, LM7, HOS, SaOS-2, ↑TIPE Modulation of miR-138 [61]
U2OS and MG-63 cells
KHOS, 143b, LM7, ↑TIPE Modulation of miR-99a [62]
U2OS and MG-63 cells
U2OS cells ↓TIPE ↑p21 [14]
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Disease Model Protein Involved Targets Associated/Outcome References
Ovarian cancer
Tissue samples ↑TIPE ↓survival [63]
OVCAR-3 cells ↓TIPE G0/G1 cell cycle arrest, ↑beclin 1,↑LC II [64]
Tissue samples ↑TIPE - [65]
Pancreatic cancer Tissue samples ↑TIPE ↑EGFR [66]
Prostate cancer
PC-3 cells ↓TIPE ↑IGFBP3, ↑NR4A1, ↑AP2A1, ↓IL5, [9]
↓MAPT, ↓TOP2A, ↓TRAF4, ↓EGFR,
↓PDCL, ↓GTF2F2, ↓GRAP2, ↓ABL1,
↓GAP43, ↓AKAP2, ↓GRIP1
PC-3 cells ↑TIPE2 ↓PI3K/Akt signaling [67]
PC-3 cells ↑TIPE ↑MMPs, ↑VEGFR-2 [68]
PC-3 cells TIPE ↑autophagy [69]
Renal cancer RCC-RS cells ↑TIPE - [39]
Thyroid cancer Tissue samples ↑TIPE - [70]
Inflammatory diseases
Atherosclerosis
Ldlr−/− female mice; two groups (wild type and TIPE2−/−) containing eight mice in
each group
↓TIPE2 ↑JNK, ↑NF-κB, ↑p38 [71]
VSMCs ↓TIPE2
↓contractile proteins, ↑synthetic
capacity for growth factors and
cytokines
[72]
Colitis
DSS induced male C57BL/6 mice (8-12 weeks old); two groups (wild type and
TIPE2−/−) ↓TIPE2 ↓TNF-α, ↓IL-6, ↓IL-12 [73]
Colonic epithelial cells ↓TIPE ↑cell death [74]
DSS-induced mice (8–10 weeks old); two groups (wild type and TIPE2−/−) ↓TIPE
↓survival rate, ↑body weight loss,
↑leukocyte infiltration, ↑bacterial
invasion, ↑inflammatory cytokine
production in the colon
Rheumatoid arthritis
AA-FLSs ↑TIPE2 ↑DR5, ↑caspase, ↓NF-κB [75]
Synovial fibroblasts ↑TIPE2 ↓Rac signaling [76]
Infectious diseases
AIH PBMCs ↓TIPE2 ↑ALT, ↑AST [77]
Hepatitis B
PBMCs ↓TIPE2 ↑perforin, ↑granzyme B, ↑IFN-γ [78]
PBMCs ↓TIPE2 ↑ALT, ↑AST, ↑total bilirubin [79]
↑HBV load
Male C57BL/6 mice (10–12 weeks old); two groups (wild type and TIPE2−/−) ↓TIPE2 ↑hepatic inflammation
Hepatitis B liver failure PBMCs ↑TIPE2 ↓TNF-α, ↓IL-6 [80]
Hepatitis B PBMCs ↑TIPE2 ↓IL-6, ↓TNF-α, ↓IFN-γ [81]
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Table 1. Cont.
Disease Model Protein Involved Targets Associated/Outcome References
Hepatitis-C induced
hepatic inflammation PBMCs ↓TIPE2 ↑TLR signaling [82]
Listeria infection HEPA1-6 cells ↓TIPE ↑apoptosis, deregulated Rac1-GTP [83]
Liver fibrosis HSC-T6 cells ↑TIPE2 ↓β-Catenin, ↓cmyc, ↓cyclin D1 [84]
Neuromuscular and neurodegenerative diseases
Myasthenia Gravis PBMCs ↓TIPE2 ↑IL-6, ↑IL-17, ↑IL-21 [85]
Parkinson’s disease Dopaminergic neurons ↑TIPE1 ↑autophagy, ↓mTORphosphorylation [86]
Other diseases
CNV RPE cells ↓TIPE2 ↑TNF-α, ↑IL-1β, ↑VEGF [87]
Diabetes Mellitus PBMCs ↑TIPE2 ↓TNF-α, ↓IL-6 [88]
Diabetic nephropathy Mesangial cells ↑TIPE
modulation of NADPH
oxidase-mediated signaling pathway [89]
Male Sprague-Dawley diabetic rats ↑TIPE -
Restenosis
VSMCs ↓TIPE2 ↑cyclin D1, ↑cyclin D3 [90]
Male C57BL/6J mice (8–12 weeks old); two groups (wild type and TIPE2−/−) ↓TIPE2 ↑severity of disease
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This review summarizes the role of this TIPE family of proteins in different chronic diseases,
their molecular targets and associated signaling cascades in different chronic diseases based on
existing literature.
2. Role of TIPE Family of Proteins in Different Chronic Diseases
2.1. TIPE Family of Protei s and Cancer
Cancer, which stems from the perturbations of multiple signaling pathways, affects people of all
ages and is a major health concern worldwide [5,91,92]. The TIPE family of proteins plays a vital role
in carcinogenesis and metastasis through its deregulated expression and function. It has been found to
be strongly associated with cancers of breast, bone, brain, cervix, colon, esophagus, endometrium, liver,
lung, stomach, and thyroid. Overall, the potential crosstalk of the four different TIPE proteins with
various signal transduction cascades in different cancers has been reviewed by our group [5] previously.
2.2. TIPE Family of Proteins and Inflammatory Diseases
TIPE and TIPE2, the regulators of immunity, have been demonstrated to protect against
inflammatory diseases such as atherosclerosis, colitis, and rheumatoid arthritis.
2.2.1. Atherosclerosis
Atherosclerosis is widely kn wn as an inflammatory diseas of the arteri l wall in w ich
macrophages play an important role. Notably, TIPE2 exhibits a high expr sion level in resting
macrophages and has been found to x ibit a potent atheropr tective role by regulating m crophage
respons to oxidized low-density lipoprotein (ox-LDL). When macrophages lacking TIPE2 were
treated with ox-LDL, it resulted in enhanced production of oxidative stress and pro-inflammatory
cytokines, as well as activation of NF-κB, JNK, and p38 signalin cascades. These results clearly implied
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TIPE2, a new-found inhibitor of atherosclerosis, to be an effective target against this disease [71].
Further, TIPE2 displayed its atheroprotective role through modulation of phenotypic switching of
vascular smooth muscle cells (VSMCs), which plays a vital role in the development of atherosclerosis
in response to ox-LDL stimuli. Ox-LDL treated TIPE2-deficient VSMCs were found to have lower
expression of contractile proteins such as smooth muscle-myosin heavy chain (SM-MHC), smooth
muscle α-actin (SmαA), and calponin, while proliferation, migration, and the synthetic ability for
cytokines and growth factors were found to increase significantly [72] (Figure 2A). Thus, these findings
clearly imply that TIPE2 is an atheroprotective protein that may serve as a potent drug candidate for
protection against this inflammatory disease.
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2.2.2. Colitis
TIPE2 plays a vital role in infla atory cell function and co ensal bacteria dissemination
regulation in dextran sodiu sulfate ( SS)-induced colitis. Lou and group observed that mice with
TIPE2 deficiency in the hematopoietic compartment survived longer compared to the wild types upon
treatment with DSS. Further, it was observed that the degree of severity of colitis, as well as colonic
damage in TIPE2-deficient mice, was notably less and was plausibly attributed to the decreased colonic
expression of inflammatory cytokines TNF-α, interleu i (IL)-6, and IL-12. In addition, it was observed
that TIPE2-deficient mic with ameliorat d DSS-induced colitis also displayed a weaker systemic
inflammatory r sponse together with reduced local dissemination of commensal b cteria [73]. Another
study investig ted the role of TIPE in DSS-induced colitis in which TIPE-deficient mice were reported
to be more prone to DSS-induced colitis, and that lack of expression of TIPE in non-hematopoietic
c lls was found to play a vital role. In TIPE knock t mice, grea reduction in body weight, the
occurrenc of severe diarrhea, rectal bleeding, a d incr ased mo tality was observed, exemplifying the
role of TIPE in protection against DSS-induced colitis [74] (Figure 2B). Altogether, thes tw findings
indicat that both TIPE and TIPE2 play importan roles in e maintenance of colon homeostasis a d
the preventio and treatment of colitis. Howev r, further in-depth studies are required to clearly
u derstand the exact molecular mechanism(s) of actions of these proteins against colitis.
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2.2.3. Rheumatoid Arthritis
Rheumatoid arthritis is a chronic inflammatory illness characterized by joint tenderness,
joint swelling, and synovial joint destruction, resulting in severe disability and premature mortality [93].
Fibroblast-like synoviocytes (FLSs) play an important role in the pathology of rheumatoid
arthritis. The study conducted by Shi and group indicated that TIPE2 increased adjuvant arthritis
(AA)-FLSs apoptosis through enhanced DR5 expression levels, thus inhibiting NF-κB activation
and promoting the activation of caspase in AA-FLSs. [75]. Further, TIPE2 was found to regulate
lipopolysaccharide-induced rat rheumatoid arthritis immune responses via activation of Rac and
phosphorylation of interferon regulatory factor 3. This study depicted TIPE2 to be inversely associated
with cytokine gene expression in synovial fibroblasts after lipopolysaccharide stimulation. Thus, TIPE2
plays a negative role in the activation of the Rac signaling pathway, as well as initiation of the
immune response via reduced function of pro-inflammatory cytokines [76] (Figure 2C). Thus, using
this novel target, TIPE2, therapeutic strategies against rheumatoid arthritis can be designed and used
for protection against this disease.
2.3. TIPE Family of Proteins and Infectious Diseases
Various studies were performed to evaluate the association of the TIPE family of proteins and
different infectious diseases such as hepatitis B, hepatitis C, listeria infection, and liver fibrosis.
2.3.1. Hepatitis B
Hepatitis B virus (HBV)-induced hepatic inflammation affects a vast majority of people across
the world and is also recognized as a prime cause of hepatic cancer. It has been reported that
TIPE2, a regulator of immune receptor signaling, can control HBV-induced hepatitis. Xi and colleagues
reported that patients with chronic hepatitis B exhibited remarkably decreased TIPE2 expression in their
peripheral blood mononuclear cells (PBMCs) compared to healthy individuals. Further, the expression
of TIPE2 negatively correlated with the blood levels of aspartate aminotransferase (AST), alanine
aminotransferase (ALT), total bilirubin, and the HBV load of the patients, suggesting that TIPE2 is
an important marker in HBV-induced hepatic inflammation [79]. In addition, the expression of TIPE2
was found to be relatively higher in acute-on-chronic hepatitis B liver failure (ACHBLF) patients
compared to healthy controls, which positively correlated with total serum bilirubin, international
normalized ratio, and the model for end-stage liver disease scores. Additionally, the TIPE2 mRNA
level was significantly higher in non-survivors compared to survivors in patients with ACHBLF,
and the TIPE2 mRNA level was found to be reduced progressively in survivors together with signs of
recovery from patients with ACHBLF. Further, lipopolysaccharide stimulation in ACHBLF patients
resulted in reduced levels of IL-6, as well as TNF-α, which displayed a negative association with
TIPE2 [80]. Another study investigated the expression of TIPE2 in mice PBMCs with autoimmune
hepatitis (AIH) and its involvement in the pathogenesis of AIH. The results showed that TIPE2 was
expressed less in AIH mice, whereas in the case of concanavalin A-induced AIH, TIPE2-deficient
mice exhibited enhanced levels of serum ALT, AST, pro-inflammatory cytokines, and severe hepatic
inflammation [77]. Zhang and group reported that the TIPE2 protein level in PBMCs of hepatitis
B patients was significantly less and negatively associated with the aminotransferases sera values.
Notably, CD8+T cells, which express a low level of TIPE2, produced significantly high granzyme B,
perforin, and interferon-γ, resulting in their enhanced cytolytic effect [78]. Further, in chronic hepatitis
B (CHB) patients, TIPE2 mRNA level in immune clearance phases was notably more compared to the
immune tolerance phase, indicating that TIPE2 might be involved in immune clearance of patients with
CHB. In addition, TNF-α, interferon-γ, and HBV DNA load were also observed to be independently
linked with the level of TIPE2 in CHB patients [81] (Figure 2D).
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2.3.2. Hepatitis C
Approximately 80% of chronic hepatitis cases are caused due to infection with Hepatitis C
virus (HCV). TIPE2 has been found to play an important role in chronic hepatitis C (CHC) infection.
Kong et al. showed that in CHC patients, TIPE2 gets significantly downregulated, whereas TLR2 and
TLR4 show upregulation when compared to healthy controls. Further, the mRNA expression level of
TIPE2 was found to be negatively associated with serum ALT, AST, and HCV RNA levels, as well as
TLR2 and TLR4 mRNA levels in CHC patients. In addition, treatment of HCV patients with ribavirin
and interferon-α led to the upregulation of TIPE2 mRNA and downregulation of TLR2 and TLR4
mRNA level [82] (Figure 2D).
Taken together, TIPE2 possesses a strong correlation with the infection with hepatitis virus,
and hence it can used as a target to develop strategies for the management of hepatitis-infected patients.
2.3.3. Listeria Infection
TIPE was reported to regulate infection with Listeria monocytogenes by controlling pathogen
invasion and host cell apoptosis in a Rac1 GTPase-dependent manner. Notably, TIPE-knockout mice
were found to be resistant to lethal Listeria monocytogenes infection, and they exerted a decreased
bacterial load in the liver and spleen. In addition, knockdown of TIPE in murine liver cells resulted in
enhanced apoptosis, reduction in bacterial invasion into cells, and deregulated Rac1 activation [83].
These findings provide understanding towards the role of TIPE2 in the pathogenesis of listeria infection,
and thus it can be used as a therapeutic target for listeriosis.
2.3.4. Liver Fibrosis
TIPE2 possesses a protective effect on liver fibrosis and hence may serve as a potent target against
this disease. TIPE2 diminished liver fibrosis through reversal of activated hepatic stellate cells. Xu et al.
demonstrated low expression of TIPE2 in CCl4-treated murine primary HSCs and activated HSC-T6
cells. Overexpression of TIPE2 hindered the activation and proliferation of HSC-T6 cells, as well as the
expression of c-myc, cyclin D1, and β-catenin, whereas its inhibition displayed the reverse effect [84]
(Figure 2E). Thus, owing to its protective effect, TIPE2 displays potential as an effective target against
liver fibrosis.
2.4. TIPE Family of Proteins in Neuromuscular and Neurodegenerative Diseases
TIPE2 and TIPE1 have been found to exert their effect in Myasthenia Gravis and Parkinson’s
disease, respectively, and thus can serve as important targets for therapies against these diseases.
2.4.1. Myasthenia Gravis
Myasthenia gravis (MG) is an autoimmune neuromuscular disease, the incidence of which is
increasing. TIPE2 has been found to play role in MG via modulation of autoimmune T helper 17 cell
responses mediated by TLR4 [85]. The study showed downregulation of TIPE2 in MG compared
to normal controls. Furthermore, TIPE2 exerted a negative association with the levels of IL-6, -17,
and -21 in the serum of MG patients. In cultured MG PBMC, TLR4 activation caused downregulation
of TIPE2, whereas RORγt expression and IL-6, -17, -21 production was enhanced. Nevertheless,
overexpression of TIPE2 abrogated the TLR4 activation-induced effects [85] (Figure 2F). Collectively,
this study provides evidence that targeting TIPE2, which functions as a negative regulator of immunity,
may offer protection against this autoimmune disease.
2.4.2. Parkinson’s Disease
Parkinson’s disease is a long-term degenerative disorder that involves the central nervous system.
Altered regulation of TIPE1 may contribute to deregulated autophagy seen in dopaminergic neurons
under pathogenic oxidative stress, which is especially observed in post-mortem brains in Parkinson’s
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disease. This protein binds to FBXW5, a tuberous sclerosis complex 2 (TSC2; a negative regulator of
mTOR) binding receptor present in CUL4 E3 ligase complex, resulting in enhanced autophagy via
activation of TSC2 in a Parkinson’s disease model. Further, oxidative, stress-induced TIPE1 caused
stabilization of TSC2 protein, reduction in mTOR phosphorylation, and an increase in autophagy [86].
Another study conducted by Kouchaki and group attempted to evaluate the association between the
serum levels and circulatory gene expression of TIPE2 with severity of Parkinson’s disease by enrolling
a total of 43 patients. The results implied that no significant differences were noted between the mean
serum levels and TIPE2 expression in patients compared to the healthy individuals. They further
showed that enhanced serum levels of TIPE2 possess a direct correlation with age and severity of
patients with Parkinson’s diseases. Besides, TIPE2 expression was also found to be strongly linked
with the age of the patients [94] (Figure 2G).
2.5. The TIPE Family of Proteins and Other Chronic Diseases
Apart from the abovementioned, this newly discovered family of proteins is strongly
involved in various other diseases such as choroidal neovascularization, restenosis, and metabolic
disease-like diabetes.
2.5.1. Choroidal Neovascularization (CNV)
Choroidal neovascularization (CNV), a pathological condition commonly occurring in ocular
diseases, is primarily characterized by vasculogenesis and angiogenesis of the neuroretina, with the
retinal pigment epithelium (RPE) as a major target. TIPE2, a negative regulator of immunity, has been
found to play a role in CNV, as inflammation and immunity are critical in the early development of
CNV. Suo and group conducted a study that reported that TIPE2 is present in human RPE cells in
the cytoplasm, as well as the nucleus, and was downregulated in the inflammatory condition, with
a subsequent reduction in cell viability. Further, knock-down of TIPE2 resulted in the upregulation
of TNF-α, IL-1β, and VEGF, especially under lipopolysaccharide induced stimuli. As TIPE2 displays
potent anti-angiogenic properties and VEGF plays a vital role in the final stage of neovascularization,
TIPE2 might take part in CNV formation [87] (Figure 2H). However, comprehensive studies are vital
to decipher the underlined molecular mechanisms through which TIPE2 function and help in the
development of CNV.
2.5.2. Diabetes
Diabetes is a type of metabolic disease associated with high blood sugar levels. Although TIPE2
plays a key role in inflammatory homeostasis, its exact role in type 2 diabetes mellitus (T2DM)
remains unknown. Liu and group reported that TIPE2 is involved in T2DM via modulation of TNF-α.
They observed an increased level of TIPE2 in T2DM patients that was positively associated with
hemoglobin A1c and low-density lipoprotein cholesterol, while it negatively correlated with serum
TNF-α, IL-6, and hsCRP concentrations in the diabetic patients. Further, treatment with high glucose
concentrations resulted in the upregulation of TIPE2 and cytokine secretion in differentiated THP-1
human monocyte cells. Additionally, TIPE2 adenovirus infection reversed the enhanced TNF-α level,
whereas treatment with siTIPE2 aggravated the enhanced level of TNF-α and IL-6 in differentiated
THP-1 cells under high glucose conditions [88]. Again, TIPE serves as a vital component of a signaling
cascade linking mesangial cell proliferation and diabetic renal injury. The study conducted by Zhang
and colleagues showed that in response to high glucose, TIPE was upregulated in mesangial cells,
and the expression of TIPE was directly correlated with mesangial cell proliferation mediated via
an NADPH oxidase-regulated signaling pathway [89] (Figure 2I).
The above studies illustrated the critical role of the two TIPE family of proteins, namely, TIPE
and TIPE2 in diabetes and diabetic nephropathy. Hence, they may serve as effective targets against
diabetes mellitus and may aid in the development of therapeutic strategies for the prevention and
treatment of this metabolic disorder.
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2.5.3. Restenosis
Restenosis is a disease characterized by smooth muscle cell hyperplasia and neointimal
formation. Zhang and group reported that TIPE2 repressed injury-induced restenosis through inhibited
proliferation of vascular smooth muscle cells (VSMCs) via modulation of ERK1/2 and Rac1-STAT3
signaling cascades. The study reported that enforced TIPE2 expression suppressed the proliferation
and blocked cell cycle progression in VSMCs, while deficiency of TIPE2 induced proliferation of
VSMCs and upregulation of cyclin D1 and cyclin D3 [90] (Figure 2J). Therefore, targeting TIPE2 might
help in designing novel approaches against restenosis.
Altogether, this family is evinced to have profound role in different chronic diseases. Interestingly,
the function of TIPE and TIPE2 in different chronic diseases and their mode of action have been studied
extensively. However, focus needs to be given to unveil the role of TIPE in various chronic diseases
other than cancer. In addition, much comprehensive studies are immensely critical to elucidate the
roles of the other two members of this family of proteins such as TIPE1 and TIPE3 in the development
of different chronic diseases and to unveil their underlined molecular mechanisms. This would help
us not only to understand their exact functions, but also to develop novel therapeutic approaches for
the prevention and treatment of diverse chronic diseases effectively.
3. Conclusions
The TIPE protein family presents a novel group of proteins discovered just a decade ago.
Expression studies of these proteins show remarkable variability among themselves. Interestingly,
although the proteins of this family were initially depicted as the modulators of tumorigenesis,
inflammation, and cell death, they were also found to possess various other functions. For instance,
TIPE and TIPE1 function as autophagy inhibitors and activators in experimental models of Parkinson’s
disease. Further, they are involved in the transfer of lipid secondary messengers PIP2 and PIP3.
Members of the TIPE family have been associated with the regulation of immune function and
homeostasis and the development of diverse cancer types. Most importantly, the members of this family
share a significant sequence homology but are involved in different biological activities. For instance,
TIPE1 exhibits a high degree of sequence homology with TIPE2. Despite the existence of a common
fold, TIPE2 plays a vital role in immune homeostasis, whereas TIPE1 may not play an essential role in
immunity. Despite the existing knowledge on this protein family in the literature, a lot more needs to
be elucidated. Though this family of proteins plays an important role in carcinogenesis, metastasis,
and development of different human chronic diseases either through up- or downregulation, its exact
molecular functions, detailed mechanism of action, and the plausible crosstalk between its members
remain ambiguous. Therefore, more comprehensive studies are imperative for better understanding
of this important family of proteins, which would provide key insights for biomarker discovery and
treatment strategies for a wide array of chronic diseases.
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Abbreviations
TIPE or TNFAIP8 Tumor necrosis factor-α-induced protein 8
TIPE1 Tumor necrosis factor-α-induced protein 8-like 1
TIPE2 Tumor necrosis factor-α-induced protein 8-like 2
TIPE3 Tumor necrosis factor-α-induced protein 8-like 3
TLR Toll-like receptor
TNF-α Tumor necrosis factor-α
FLIP Fas-associated death domain-like interleukin-1β-converting enzyme-inhibitory protein
mTOR Mammalian target of rapamycin
NF-κB Nuclear factor κ-light-chain-enhancer of activated B cells
MAPK Mitogen-activated protein kinase
MMP Matrix metalloproteinase
VEGF Vascular endothelial growth factor
DLBCL Diffuse large B-cell lymphoma
EMT Epithelial-to-mesenchymal transition
EC Endometrial carcinoma
ESCC Esophageal squamous cell carcinoma
ERK1/2 Extracellular signal-regulated kinase 1/2
HCC Hepatocellular carcinoma
NHL Non-Hodgkin’s lymphoma
PTCL Peripheral T-cell lymphoma
NSCLC Non-small cell lung cancer
OS Osteosarcoma
CNV Choroidal neovascularization
T2DM Type 2 diabetes mellitus
MG Myasthenia gravis
HBV Hepatitis B virus
HCV Hepatitis C virus
AIH Autoimmune hepatitis
AST Aspartate aminotransferase
ALT Alanine aminotransferase
PBMCs Peripheral blood mononuclear cells
DSS Dextran sodium sulfate
IL-6 Interleukin-6
Ox-LDL Oxidized low-density lipoprotein
VSMCs Vascular smooth muscle cells
SM-MHC Smooth muscle-myosin heavy chain
SmαA Smooth muscle α-actin
FLSs Fibroblast-like synoviocytes
AA Adjuvant arthritis
RPE Retinal pigment Epithelium
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